Portal vein tumor thrombosis (PVTT) is a common paraneoplastic condition in advanced primary hepatocellular carcinoma or hepatobiliary tract malignancies. Tumors with PVTT are frequently associated with adverse and aggressive features such as intrahepatic tumor dissemination, early treatment failure, or deterioration of hepatic function. Therefore, the treatment outcomes for PVTT in historical series are often dismal and discouraging. More recently, beneficial effects and excellent outcomes of external beam radiation therapy (EBRT) for treating this disease have been reported, and the use of EBRT is becoming more common because of the non-invasive nature of RT and rapid advances in RT technology. We hope to be able to cure this devastating condition in the near future with more advanced and efficacious disease management strategies. The current status and clinical trial results for EBRT as a promising treatment option for managing PVTT will be discussed here.

Keywords:
Hepatocellular carcinoma, Portal vein tumor thrombosis, Radiotherapy
1.
Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Seo HG, Lee JS: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat 2012;44:11-24.
2.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3.
Bashir MR, Gupta RT, Davenport MS, Allen BC, Jaffe TA, Ho LM, Boll DT, Merkle EM: Hepatocellular carcinoma in a North American population: Does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? J Magn Reson Imaging. 2013;37:398-406.
4.
Choi BO, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, Yoon SK, Chai GY, Kang KM: Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer 2008;8:351.
5.
Corvalan AH: Early diagnosis of hepatocellular carcinoma by microRNAs: shining a light from the genome's “dark matter”. Dig Dis Sci 2012;57:2737-2739.
6.
Hawkins MA, Dawson LA: Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006;106:1653-1663.
7.
Seong J: Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J 2009;50:601-612.
8.
Ogren M, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH: Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006;12:2115-2119.
9.
Fan J, Wu ZQ, Tang ZY, Zhou J, Qiu SJ, Ma ZC, Zhou XD, Ye SL: Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J Gastroenterol 2001;7:28-32.
10.
Ishikura S, Ogino T, Furuse J, Satake M, Baba S, Kawashima M, Nihei K, Ito Y, Maru Y, Ikeda H: Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002;25:189-193.
11.
Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, Chung YH, Lee YS, Lee SG, Park JH, Suh DJ: Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012;82:2004-2011.
12.
Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee PC, Loong CC, Chiang JH, Huo TI, Lee SD: Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 2010;116:3006-3014.
13.
Kim BK, Kim SU, Park JY, Kim do Y, Ahn SH, Park MS, Kim EH, Seong J, Lee do Y, Han KH: Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naive patients with hepatocellular carcinoma. Liver Int 2012;32:1120-1127.
14.
Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012;1:41-50.
15.
Kudo M: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012;1:62-70.
16.
Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, Lee YS, Sung KB, Suh DJ: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986-1991.
17.
Kondo K, Chijiiwa K, Kai M, Otani K, Nagaike K, Ohuchida J, Hiyoshi M, Nagano M: Surgical strategy for hepatocellular carcinoma patients with portal vein tumor thrombus based on prognostic factors. Journal Gastrointest Surg 2009;13:1078-1083.
18.
Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M: Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011;18:413-420.
19.
Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX: NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009;7:350-391.
20.
Dawson LA, Ten Haken RK: Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005;15:279-283.
21.
Kim DY, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, Kho KC, Kim TH, Ahn YC, Huh SJ: Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005;103:2419-2426.
22.
Sugahara S, Oshiro Y, Nakayama H, Fukuda K, Mizumoto M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tokita M, Tsuboi K, Tokuuye K: Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010;76:460-466.
23.
Jihye C, Jinsil S: Application of radiotherapeutic strategies in the BCLC-defined stages of hepatocellular carcinoma. Liver Cancer 2012;1:216-225.
24.
Nakazawa T, Adachi S, Kitano M, Isobe Y, Kokubu S, Hidaka H, Ono K, Okuwaki Y, Watanabe M, Shibuya A, Saigenji K: Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels. Oncology 2007;73:90-97.
25.
Mitsunobu M, Toyosaka A, Oriyama T, Okamoto E, Nakao N: Intrahepatic metastases in hepatocellular carcinoma: the role of the portal vein as an efferent vessel. Clin Exp Metastasis 1996;14:520-529.
26.
Lin DX, Zhang QY, Li X, Ye QW, Lin F, Li LL: An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus. J Cancer Res Clin Oncol 2011;137:139-149.
27.
Liu J, Wang Y, Zhang D, Liu B, Ou Q: Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. Eur J Gastroenterol Hepatol 2012;24:186-194.
28.
Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, Poon RT: Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009;115:428-436.
29.
Song MJ, Chun HJ, Song S, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY, Chang UI, Yang JM, Lee HG, Yoon SK: Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012;57:1244-1250.
30.
Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF, Zhang BX, He SQ, Zhang WG: Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol 2006;13:940-946.
31.
Matono R, Yoshiya S, Motomura T, Toshima T, Kayashima H, Masuda T, Yoshizumi T, Taketomi A, Shirabe K, Maehara Y: Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection. HPB (Oxford) 2012;14:247-253.
32.
Chan MK, Kwok PC, Chan SC, Lam TW, Lo KK, Lam CL: Percutaneous ethanol injection as a possible curative treatment for malignant portal vein thrombosis in hepatocellular carcinoma. Cardiovasc Intervent Radiol 1999;22:326-328.
33.
Novi M, Lauritano EC, Piscaglia AC, Barbaro B, Zocco MA, Pompili M, Gasbarrini A: Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol 2009;104:1852-1854.
34.
Basso M, Basso M, Iaculli A, Pompili M, Riccardi L, Barbaro B, Rufini V, Cassano A, Castaldi P, Barone C: Complete metabolic response with recanalization of portal vein tumor thrombosis after sunitinib in a patient with advanced hepatocellular carcinoma. Case reports in oncology 2010;3:391-396.
35.
Han KH, Seong J, Kim JK, Ahn SH, Lee Y, Chon CY: Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis . Cancer 2008;113:995 - 1003.
36.
Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM: Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 2006;29:568-575.
37.
Yu JI, Park HC, Lim H, Park W, Yoo BC, Paik SW, Koh KC, Lee JH: Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy. J Korean Med Sci 2011;26:1014-1022.
38.
Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW: Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010;10:475.
39.
Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Kenjo M, Toyota N, Ito K, Chayama K: Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol 2009;44:492-502.
40.
Nakagawa K, Yamashita H, Shiraishi K, Nakamura N, Tago M, Igaki H, Hosoi Y, Shiina S, Omata M, Makuuchi M, Ohtomo K: Radiation therapy for portal venous invasion by hepatocellular carcinoma. World J Gastroenterol 2005;11:7237-7241.
41.
Tazawa J, Maeda M, Sakai Y, Yamane M, Ohbayashi H, Kakinuma S, Miyasaka Y, Nagayama K, Enomoto N, Sato C: Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001;16:660-665.
42.
Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, Matsumoto S, Soejima T, Sugimura K: Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113-119.
43.
Zeng ZC, Fan J, Tang ZY, Zhou J, Qin LX, Wang JH, Sun HC, Wang BL, Zhang JY, Jiang GL, Wang YQ: A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005;61:432-443.
44.
Zhang XB, Wang JH, Yan ZP, Qian S, Du SS, Zeng ZC: Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. Cancer 2009;115:1245-1252.
45.
Rim CH, Yang DS, Park YJ, Yoon WS, Lee JA, Kim CY: Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis. Jpn J Clin Oncol 2012;42:721-729.
46.
Toya R, Murakami R, Baba Y, Nishimura R, Morishita S, Ikeda O, Kawanaka K, Beppu T, Sugiyama S, Sakamoto T et al: Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol 2007;84:266-271.
47.
Hou JZ, Zeng ZC, Zhang JY, Fan J, Zhou J, Zeng MS: Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion. Int J Radiat Oncol Biol Phys 2012;84:362-368.
48.
You CR, Jang JW, Kang SH, Bae SH, Choi JY, Yoon SK, Choi IB, Lee DH, Chun HJ, Choi BG: Efficacy of transarterial chemolipiodolization with or without 3-dimensional conformal radiotherapy for huge HCC with portal vein tumor thrombosis. Korean J Hepatol 2007;13:378-386.
49.
Chon YE, Seong J, Kim BK, Cha J, Kim SU, Park JY, Ahn SH, Han KH, Chon CY, Shin SK, Kim Y: Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors. Int J Radiat Oncol Biol Phys 2011;81:1343-1351.
50.
Wu DH, Chen LH: Efficacy of 3-dimensional conformal hypofractionated single high-dose radiotherapy combined with transcatheter arterial chemoembolization for portal vein tumor thrombus in patients with hepatocellular carcinoma. Chin J Cancer 2004;23:825-828.
51.
Lee IJ, Seong J: The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver 2012;6:139-148.
52.
Xi M, Liu MZ, Zhang L, Li QQ, Huang XY, Liu H, Hu YH: How many sets of 4DCT images are sufficient to determine internal target volume for liver radiotherapy? Radiother Oncol 2009;92:255-259.
53.
Kagan AR, Schulz RJ: Proton-beam therapy for prostate cancer. Cancer J 2010;16:405-409.
54.
Zenda S, Kohno R, Kawashima M, Arahira S, Nishio T, Tahara M, Hayashi R, Kishimoto S, Ogino T: Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys 2011;81:1473-1478.
55.
Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tsuboi K, et al: Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlentherapie und Onkologie. Organ Dtsch Rontgengesellschaft 2009;185:782-788.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.